VIKING THERAPEUT.DL -,005 WKN: A12GD6 ISIN: US92686J1060 Kürzel: VKTX Forum: Aktien Thema: Hauptdiskussion

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity. Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.) Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.) The Phase 3 VANQUISH-1 study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks. The trial enrolled approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. Enrolled patients have been randomized to one of four weekly treatment arms: VK2735 7.5 mg, 12.5 mg, 17.5 mg, and placebo. The primary endpoint of the trial is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment. Secondary and exploratory endpoints are evaluating a range of additional safety and efficacy measures, including the percentage of patients who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction. The study includes a 52-week extension period allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period. "We are excited to announce completion of enrollment in VANQUISH-1 ahead of schedule," said Brian Lian, Ph.D., chief executive officer of Viking. "As with prior VK2735 studies, the trial accrued rapidly and exceeded our enrollment target. We believe this speaks to the enthusiasm for new obesity treatments beyond those currently available. We look forward to completing enrollment in the VANQUISH-2 study in the first quarter of 2026." Concurrently, Viking is conducting the Phase 3 VANQUISH-2 study of subcutaneous VK2735 in patients with type 2 diabetes who have obesity or are overweight. That trial is currently enrolling patients, and the company expects to complete enrollment in the first quarter of 2026.